Tag: ai-biotech
-
The Target Identification Problem
Target identification remains the largest source of late-stage clinical failure in drug development. Here's why AI hasn't solved it and what would actually help.
-
Generative Chemistry
Generative AI models are designing drug molecules from scratch. Here's what the chemistry literature reveals about their capabilities, limitations, and failure modes.
-
The FDA and the Machine
The FDA faces the novel challenge of regulating AI-discovered drugs and AI-assisted diagnostics. The institutional response is more sophisticated than critics acknowledge.
-
The Billion-Dollar Bet on Longevity
Longevity biotech has raised billions on AI-accelerated aging science. Here's an honest look at what the biology supports and where the hype has overrun the evidence.
-
Clinical Trial Design: The Hidden Frontier Where AI Is Winning
AI is improving clinical trial success rates not through molecule design but by identifying the right patients, designing smarter protocols, and predicting trial failure early.
-
The Antibody Engineers
AI-driven antibody engineering is producing therapeutics with properties that natural evolution wouldn't generate. Here's what that capability means for medicine.
-
The Recursion Bet
Recursion Pharmaceuticals built a biological data factory and bet everything on phenomics. Here's what their pipeline reveals about the limits of industrialized discovery.
-
AlphaFold Three Years Later
AlphaFold solved a 50-year problem in structural biology. Here's an honest audit of what that achievement has and hasn't delivered for drug discovery by 2026.
-
Molecules by Machine
AI-designed molecules are entering Phase I and II trials. Here's an honest accounting of which ones, by whom, and what the early data actually shows.
